http://www.cnr.it/ontology/cnr/individuo/prodotto/ID10471

Change in glucose metabolism measured by 18F-FDG PET/CT as a predictor of histopathologic response to neoadjuvant treatment in rectal cancer. (Articolo in rivista)

Type

Prodotto della ricerca (Classe)
Articolo in rivista (Classe)

Label

Change in glucose metabolism measured by 18F-FDG PET/CT as a predictor of histopathologic response to neoadjuvant treatment in rectal cancer. (Articolo in rivista) (literal)

Anno

2011-01-01T00:00:00+01:00 (literal)

Alternative label

Guerra L. 1, Niespolo R. 2, Di Pisa G. 1, Ippolito D. 3, De Ponti E. 4, Terrevazzi S. 2, Bovo G. 5, Sironi S. 3, Gardani G. 2, Messa C. 1,6 (2011)
Change in glucose metabolism measured by 18F-FDG PET/CT as a predictor of histopathologic response to neoadjuvant treatment in rectal cancer.
in Abdominal imaging
(literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#autori

Guerra L. 1, Niespolo R. 2, Di Pisa G. 1, Ippolito D. 3, De Ponti E. 4, Terrevazzi S. 2, Bovo G. 5, Sironi S. 3, Gardani G. 2, Messa C. 1,6 (literal)

Pagina inizio

38 (literal)

Pagina fine

45 (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#numeroVolume

36 (literal)

Rivista

Abdominal imaging (Rivista)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#note

Pubblicato on-line: 22 Dicembre 2009. Corresponding author: C. Messa (c.messa@hsgerardo.org) IF 2010: 1.950 (literal)

Note

ISI Web of Science (WOS) (literal)

Http://www.cnr.it/ontology/cnr/pubblicazioni.owl#affiliazioni

1. Department of Nuclear Medicine and PET Unit-Molecular Bioimaging Centre, San Gerardo Hospital-University of Milan-Bicocca, Monza. 2. Department of Radiation Oncology, San Gerardo Hospital-University of Milan-Bicocca, Monza 3. Department of Radiology, San Gerardo Hospital-University of Milan-Bicocca, Monza 4. Department of Medical Physics, San Gerardo Hospital, Monza. 5. Department of Pathology, San Gerardo Hospital-University of Milan-Bicocca, Monza 6. University of Milan-Bicocca, IBFM-CNR, Segrate (MI) (literal)

Titolo

Change in glucose metabolism measured by 18F-FDG PET/CT as a predictor of histopathologic response to neoadjuvant treatment in rectal cancer. (literal)

Abstract

PURPOSE: In order to analyze the changes of glucose metabolism by maximum standardized uptake value (SUVmax) of 18F-FDG PET/CT in patients with rectal cancer submitted to neoadjuvant radiochemotherapy (nRCT) and to correlate SUV changes with tumor regression grade (TRG). METHODS AND MATERIAL: Three sequential 18F-FDG PET/CT studies were performed in 31 patients with rectal cancer at the following time point: before starting the treatment (PET/CT1), during the treatment (PET/CT2), and after completion of neoadjuvant treatment (PET/CT3). The SUVmax values of the rectal lesion in the PET/CT1 (SUV1), PET/CT2 (SUV2), and PET/CT3 (SUV3) were obtained; deltaSUV1 [(SUV1 - SUV2)/SUV1] and deltaSUV2 [(SUV1 - SUV3)/SUV1] were also calculated. Metabolic parameters were compared to TRG. RESULTS: Significant differences in pathologic responder and non-responder patients were found only for SUV2 (6.4 +/- 2.9 in responder and 10.7 +/- 4.8 in non-responder patients, respectively; P = 0.006) and SUV3 (3.6 +/- 1.4 in responder and 6.6 +/- 2.1 in non-responder patients, respectively; P = 0.0009). The best predictor for TRG response was SUV3 (threshold of 4.4) with sensitivity, specificity, accuracy, negative predictive value, and positive predictive value of 77.3%, 88.9%, 80.7%, 61.5%, and 94.4%, respectively. CONCLUSION: 18F-FDG PET/CT is a reliable and accurate technique to assess the response to nRCT in rectal cancer. In our population, the absolute value of SUVmax after treatment was the best predictor of pathological response. (literal)

Prodotto di